Skip to main content

Advertisement

SpringerLink
Log in

A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Granisetron is a safe and effective prophylaxis for nausea and vomiting associated with moderate to highly emetogenic chemotherapy. Few trials have been conducted to determine the optimal effective dose of granisetron in children with cancer. The objective of this report was to compare two doses of granisetron in patients with optic pathway tumors receiving moderately emetogenic doses of carboplatin.

Patients and methods

In this double-blind, crossover, randomized study, antiemetic efficacy and tolerability of two dose levels (10 and 40 μg/kg) of granisetron in the prevention of acute and delayed nausea/emesis were compared in children and young adults. A total of 18 patients (13 boys) aged 1–23 years (median 7.7 years) treated with a moderately emetogenic dose of carboplatin were randomly assigned to receive either 10 or 40 μg/kg of slow granisetron intravenous (i.v.) infusions at alternating cycles of chemotherapy in a blinded fashion until the end of the study period or until their chemotherapy regimen ended. In this way, the patients acted as their own controls.

Results

Patients in the granisetron 10 and 40 μg/kg groups received 104 and 121 cycles of chemotherapy, respectively. There was no significant difference in antiemetic efficacy in terms of nausea and emesis between the dose groups in the first 5 days of chemotherapy. The treatment was well tolerated.

Conclusion

We conclude that granisetron 10 and 40 μg/kg have comparable efficacy in controlling carboplatin-induced acute and delayed nausea/emesis and is well tolerated in children and young adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. ASHP (1999) Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729–764

    Google Scholar 

  2. Aapro M (2004) Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 9:673–686

    Article  PubMed  CAS  Google Scholar 

  3. Aapro MS, Thuerlimann B, Sessa C et al; Swiss Research Group for Clinical Cancer Research (2003) A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14:291–297

    Article  PubMed  CAS  Google Scholar 

  4. Aksoylar S, Akman SA, Ozgenc F et al (2001) Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 18:397–406

    Article  PubMed  CAS  Google Scholar 

  5. Craft AW, Price L, Eden OB et al (1995) Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 25:28–32

    Article  PubMed  CAS  Google Scholar 

  6. de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061

    PubMed  Google Scholar 

  7. Gandara D (1991) Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 27:S9–S11 (discussion S22)

    Article  PubMed  Google Scholar 

  8. Gandara DR, Roila F, Warr D et al (1998) Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 6:237–243

    Article  PubMed  CAS  Google Scholar 

  9. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994

    PubMed  CAS  Google Scholar 

  10. Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55:173–189

    Article  PubMed  CAS  Google Scholar 

  11. Hahlen K, Quintana E, Pinkerton CR et al (1995) A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 126:309–313

    Article  PubMed  CAS  Google Scholar 

  12. Herrstedt J, Koeller JM, Roila F et al (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:97–103

    Article  PubMed  Google Scholar 

  13. Holdsworth MT, Raisch DW, Frost J (2006) Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 106:931–940

    Article  PubMed  Google Scholar 

  14. Jacobson SJ, Shore RW, Greenberg M et al (1994) The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy. Am J Pediatr Hematol/Oncol 16:231–235

    Article  CAS  Google Scholar 

  15. Kamanabrou D (1992) Intravenous granisetron-establishing the optimal dose. The Granisetron Study Group. Eur J Cancer 28A:S6–S11

    Article  PubMed  Google Scholar 

  16. Koizumi W, Tanabe S, Nagaba S et al (2003) A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy 49:316–323

    Article  PubMed  CAS  Google Scholar 

  17. Komada Y, Matsuyama T, Takao A et al (1999) A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 35:1095–1101

    Article  PubMed  CAS  Google Scholar 

  18. Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85–96

    Article  PubMed  Google Scholar 

  19. Lemerle J, Amaral D, Southall DP et al (1991) Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 27:1081–1083

    PubMed  CAS  Google Scholar 

  20. Luisi FA, Petrilli AS, Tanaka C et al (2006) Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 124:61–65

    Article  PubMed  Google Scholar 

  21. Mabro M, Cohn R, Zanesco L et al (2000) Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses. Bull Cancer 87:259–264 (French)

    PubMed  CAS  Google Scholar 

  22. Matsui K, Fukuoka M, Takada M et al (1996) Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 73:217–221

    PubMed  CAS  Google Scholar 

  23. Miyajima Y, Numata S, Katayama I et al (1994) Prevention of chemotherapy-induced emesis with granisetron in children with malignant diseases. Am J Pediatr Hematol/Oncol 16:236–241

    Article  CAS  Google Scholar 

  24. Navari R, Gandara D, Hesketh P et al (1995) Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 13:1242–1248

    PubMed  CAS  Google Scholar 

  25. Orchard PJ, Rogosheske J, Burns L et al (1999) A prospective randomized trial of the antiemetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 5:386–393

    Article  PubMed  CAS  Google Scholar 

  26. Redmond K (1996) Advances in supportive care. Eur J Cancer Care (Engl) 4:1–7

    Article  Google Scholar 

  27. Riviere A (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer 68:967–971

    Google Scholar 

  28. Soukop M (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer 2:177–183

    Article  PubMed  CAS  Google Scholar 

  29. Tsuchida Y, Hayashi Y, Asami K et al (1999) Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 14:673–679

    PubMed  CAS  Google Scholar 

  30. Yalcin S, Tekuzman G, Baltali E et al (1999) Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol 22:94–96

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was presented in part at the 38th Annual Conference of the International Society of Paediatric Oncology (SIOP) 2006, Geneva, Switzerland, 18–21 September 2006.

Author information

Author notes

  1. Su G. Berrak

    Present address: , Hamidiye M, Ulubatli Hasan C, Tiryaki A4/16, 34782, Cekmekoy, Istanbul, Turkey

Authors and Affiliations

  1. Pediatric Hematology Oncology, Marmara University Medical Center, Altunizade, Istanbul, Turkey

    Su G. Berrak, Cengiz Canpolat & Bahar Beker

  2. Pediatrics, Marmara University Medical Center, Altunizade, Istanbul, Turkey

    Nihal Ozdemir

  3. Public Health, Marmara University Medical Center, Haydarpasa, Istanbul, Turkey

    Nadi Bakirci

  4. Pediatric Hematology, Ministry of Health Okmeydani Educational and Research Hospital, Okmeydani, Istanbul, Turkey

    Emine Turkkan

  5. Pediatric Oncology, Ministry of Health Goztepe Educational and Research Hospital, Goztepe, Istanbul, Turkey

    Asim Yoruk

Authors
  1. Su G. Berrak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nihal Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nadi Bakirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emine Turkkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cengiz Canpolat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bahar Beker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Asim Yoruk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Su G. Berrak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berrak, S.G., Ozdemir, N., Bakirci, N. et al. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 15, 1163–1168 (2007). https://doi.org/10.1007/s00520-007-0242-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-007-0242-y

Keywords

Search

Navigation